NGS-Based Antibody Library Quality and Biopanning Control

Biopharma Partner Symposium, Boston, MA, USA
March 6, 2023

Nanobodies are camelid heavy chain-only antibodies, whose small size makes them easier to engineer, while providing distinct therapeutic advantages. Next-generation sequencing (NGS) is emerging as a complimentary tool in the analysis of nanobody and antibody libraries that underwent selection via phage-display biopanning, where traditional approaches may yield only a limited number of potential binders.

Genedata Selector^® supports deep sequencing of such libraries, which enables the identification of more high-affinity binders within a much broader sequence space. This facilitates targetting of multiple different antigen epitopes, based on complementarity-determining region (CDR) homology, and the generation of backup candidates.